MARKET

LUMO

LUMO

Lumos Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.63
-0.27
-1.94%
Closed 16:00 10/20 EDT
OPEN
13.93
PREV CLOSE
13.90
HIGH
13.95
LOW
13.63
VOLUME
7.71K
TURNOVER
--
52 WEEK HIGH
32.40
52 WEEK LOW
6.74
MARKET CAP
113.04M
P/E (TTM)
-2.1663
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in September
GlobeNewswire · 08/27 14:00
Lumos Pharma, Inc. 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2020 Q2 earnings call.
Seekingalpha · 08/14 16:51
Lumos Pharma Q2 EPS $(0.65) Up From $(2.47) YoY, Sales $33.00K
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.65) per share. This is a 73.68 percent increase over losses of $(2.47) per share from the same period last year. The company reported $33.00 thousand in sales
Benzinga · 08/13 20:10
Lumos Pharma EPS beats by $0.05
Lumos Pharma (LUMO): Q2 GAAP EPS of -$0.65 beats by $0.05.Revenue of $0.03MPress Release
Seekingalpha · 08/13 20:03
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 12:18
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2020 financial results after market close
GlobeNewswire · 07/28 20:01
Lumos Pharma shares are trading higher after the company announced the sale of its Priority Review Voucher for $100 million. UPDATE: Shares have since reversed, now lower.
Benzinga · 07/28 14:01
TCOM, PII among premarket gainers
Seeking Alpha · 07/28 12:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LUMO. Analyze the recent business situations of Lumos Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LUMO stock price target is 33.00 with a high estimate of 51.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 5.87M
% Owned: 70.82%
Shares Outstanding: 8.29M
TypeInstitutionsShares
Increased
10
249.31K
New
15
54.30K
Decreased
9
21.92K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
Richard Hawkins
Chief Financial Officer
Carl Langren
Chief Executive Officer
Brad Powers
Chief Operating Officer/Chief Scientific Officer
John McKew
Senior Vice President - Finance/Chief Accounting Officer/Controller
Lori Lawley
General Counsel
Bradley Powers
Other
Eugene Kennedy
Other
Aaron Schuchart
Lead Director/Independent Director
Thomas Raffin
Director
Nicholas Vahanian
Director
Joe McCracken
Independent Director
Emmett Cunningham
Independent Director
Chad Johnson
Independent Director
Kevin Lalande
Independent Director
Joseph McCracken
Independent Director
Lota Zoth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LUMO
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.